• A grant agreement issued by the United States Patent and Trademark Office
• This new patent will protect OSE-279 until 2039
Nantes, France – March 21, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the United States Patent and Trademark Office (USPTO) has granted a first approval for Issuance of a patent relating to OSE-279, an anti-PD1 monoclonal antibody, and its use in the treatment of cancer. This patent will strengthen the worldwide intellectual property of OSE-279 and protect the product until 2039.